Logo image of DRUG

BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Fundamental Analysis

USA - NASDAQ:DRUG - CA10919W4056 - Common Stock

63.29 USD
+1.88 (+3.06%)
Last: 10/10/2025, 9:22:02 PM
63.62 USD
+0.33 (+0.52%)
After Hours: 10/10/2025, 9:22:02 PM
Fundamental Rating

2

Overall DRUG gets a fundamental rating of 2 out of 10. We evaluated DRUG against 537 industry peers in the Biotechnology industry. While DRUG seems to be doing ok healthwise, there are quite some concerns on its profitability. DRUG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DRUG has reported negative net income.
In the past year DRUG has reported a negative cash flow from operations.
In the past 5 years DRUG always reported negative net income.
DRUG had a negative operating cash flow in each of the past 5 years.
DRUG Yearly Net Income VS EBIT VS OCF VS FCFDRUG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.99%, DRUG is in the better half of the industry, outperforming 79.89% of the companies in the same industry.
With an excellent Return On Equity value of -17.20%, DRUG belongs to the best of the industry, outperforming 86.59% of the companies in the same industry.
Industry RankSector Rank
ROA -16.99%
ROE -17.2%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRUG Yearly ROA, ROE, ROICDRUG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DRUG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRUG Yearly Profit, Operating, Gross MarginsDRUG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

DRUG has more shares outstanding than it did 5 years ago.
DRUG Yearly Shares OutstandingDRUG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2024 1M 2M 3M 4M
DRUG Yearly Total Debt VS Total AssetsDRUG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2024 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 564.03 indicates that DRUG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 564.03, DRUG belongs to the top of the industry, outperforming 99.81% of the companies in the same industry.
DRUG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, DRUG is in line with its industry, outperforming 48.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 564.03
ROIC/WACCN/A
WACCN/A
DRUG Yearly LT Debt VS Equity VS FCFDRUG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 86.56 indicates that DRUG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 86.56, DRUG belongs to the top of the industry, outperforming 99.81% of the companies in the same industry.
A Quick Ratio of 86.56 indicates that DRUG has no problem at all paying its short term obligations.
DRUG's Quick ratio of 86.56 is amongst the best of the industry. DRUG outperforms 99.81% of its industry peers.
Industry RankSector Rank
Current Ratio 86.56
Quick Ratio 86.56
DRUG Yearly Current Assets VS Current LiabilitesDRUG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for DRUG have decreased strongly by -43.54% in the last year.
EPS 1Y (TTM)-43.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1595.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DRUG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRUG Price Earnings VS Forward Price EarningsDRUG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRUG Per share dataDRUG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DRUG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIGHT MINDS BIOSCIENCES INC

NASDAQ:DRUG (10/10/2025, 9:22:02 PM)

After market: 63.62 +0.33 (+0.52%)

63.29

+1.88 (+3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)N/A N/A
Inst Owners68.05%
Inst Owner Change0%
Ins Owners22.63%
Ins Owner ChangeN/A
Market Cap448.09M
Analysts85.71
Price TargetN/A
Short Float %3.96%
Short Ratio2.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.12
P/tB 12.12
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS5.22
TBVpS5.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.99%
ROE -17.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 86.56
Quick Ratio 86.56
Altman-Z 564.03
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1595.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-151.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.86%
OCF growth 3YN/A
OCF growth 5YN/A